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Abstract: Bergamottin (BM, 1), a component of grapefruit juice, acts as an inhibitor of some isoforms
of the cytochrome P450 (CYP) enzyme, particularly CYP3A4. Herein, a new bergamottin containing a
nitroxide moiety (SL-bergamottin, SL-BM, 10) was synthesized; chemically characterized, evaluated
as a potential inhibitor of the CYP2C19, CYP3A4, and CYP2C9 enzymes; and compared to BM
and known inhibitors such as ketoconazole (KET) (3A4), warfarin (WAR) (2C9), and ticlopidine
(TIC) (2C19). The antitumor activity of the new SL-bergamottin was also investigated. Among the
compounds studied, BM showed the strongest inhibition of the CYP2C9 and 2C19 enzymes. SL-BM
is a more potent inhibitor of CYP3A4 than the parent compound; this finding was also supported by
docking studies, suggesting that the binding positions of BM and SL-BM to the active site of CYP3A4
are very similar, but that SL-BM had a better ∆Gbind value than that of BM. The nitroxide moiety
markedly increased the antitumor activity of BM toward HeLa cells and marginally increased its
toxicity toward a normal cell line. In conclusion, modification of the geranyl sidechain of BM can
result in new CYP3A4 enzyme inhibitors with strong antitumor effects.
Keywords: bergamottin; nitroxide; CYP3A4 inhibition; anticancer activity
1. Introduction
Bergamottin (i.e., 5-geranoxypsoralen (1)) is a natural furanocoumarin that was originally detected
in bergamot oil (Citrus bergamia) [1] and is mainly responsible, together with 6′,7′-dihydroxybergamottin
(DHB, 2), for “grapefruit juice/drug” interactions (Figure 1). Grapefruit juice has been found to cause
a marked increase in the oral bioavailability of many therapeutic agents (e.g., dihydropyridines [2],
ethinylestradiol [3], midazolam [4], cyclosporine A [5], and lovastatin [6]) primarily by inhibiting the
CYP3A4 enzyme. Several mechanisms have been reported regarding the CYP3A4 inhibitory effect of
bergamottin such as decreased protein expression or the reversible inhibition of the enzyme [7–10].
Row et al. studied the inhibitory effects of a series of furanocoumarin analogues on the CYP3A4
enzyme. They found that the furan ring and the alkyloxy group were necessary for inhibition,
and hydrophilic groups at 6′,7′-positions enhanced the potency compared to the alkenyl group [11].
Int. J. Mol. Sci. 2020, 21, 508; doi:10.3390/ijms21020508 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 508 2 of 13
Although bergamottin is a less potent CYP3A4 inhibitor than DHB [12], it is a stronger inhibitor of some
other CYP subfamilies such as CYP1A and 2B [13]. Bergamottin was also found to inhibit CYP2A6,
2C9, 2C19, 2D6, and 2E1 enzymes in human liver microsomes [14].
Bergamottin appeared to be a potential anticancer agent against various tumor cell lines by
the regulation of several cancer-related pathways [15]. Through the inhibition of STAT3 activation,
BM inhibited the proliferation of breast cancer cells and multiple myeloma [16]. BM attenuated
cell migration and invasion of fibrosarcoma and lung cancer cell lines [17,18]. In combination with
simvastatin, BM suppressed the TNF-α-induced anti-proliferative and pro-apoptotic processes of
KBM-5 myeloid leukemia cells [19].
Figure 1. Chemical structures of bergamottin (1) and 6′,7′-dihydroxybergamottin (2).
The unpaired electrons of stable nitroxide free radicals allow the nitroxides to take part
in one-electron oxidation and reduction processes, which make nitroxides potent unnatural
antioxidants [20]. As a consequence, nitroxides exert a cytoprotective action against oxidative
stress induced by cytotoxic drugs or pathological processes, such as ischemia-reperfusion and
inflammation [21–23]. However, some piperidine types of nitroxides also exert cytotoxic and
pro-oxidant effects, particularly on cancer cells [24,25].
We have reported in several studies that the modification of biomolecules (caffeic acid phenethyl
ester, resveratrol, and curcumin) with nitroxides for use as “in statu nascendi acting” antioxidants may
be beneficial on their activity. For instance, better antioxidant, antiproliferative, anti-inflammatory and
cell-protective compounds can be achieved by these modifications [26–31].
Herein, we report the synthesis, CYP (2C9, 2C19, and 3A4) enzyme inhibition, and the anticancer
activity of a new paramagnetic bergamottin analog compared to the parent compound and known
CYP inhibitors. Furthermore, CYP3A4 enzyme inhibition was also evaluated by docking studies.
2. Results
2.1. Synthesis of Spin-Labelled Geraniol (7)
For the synthesis of nitroxide-modified geraniol (7), the first step was to alkylate the ethyl
acetoacetate with paramagnetic allylic bromide (3) [32] in acetone and in the presence of K2CO3 at
ambient temperature to obtain compound 4 with 67% yield. The ketoester was hydrolyzed with
a NaOH/ethanol solution and then acidified with aq. H2SO4. The elimination of CO2 happened
spontaneously to yield ketone 5, in which the Horner–Wadsworth–Emmons reaction with triethyl
phosphonoacetate led to the formation of paramagnetic Z/E esters (6) at a 1:4 ratio. After purification,
the reduction of E-ester 6 with sodium-bis (2-methoxyethoxy) aluminum hydride (SMEAH) in anhydrous
toluene afforded E-4-(6-hydroxy-4-methyl-4-hexene-1-ylidene)-2,2,6,6-tetramethyl-piperidine-1-oxyl (7,
spin-labelled geraniol) (Scheme 1).
2.2. Synthesis of Spin-Labelled Bergamottin (10)
The alkylation of 4-hydroxy-7H-furo[3,2-g]chromen-7-one (bergaptol, 9) may result in new
bergamottin derivatives. To achieve a nitroxide ring motif containing bergamottin (10), paramagnetic
geranyl bromide (8) was synthesized via the treatment of 7 with methanesulfonyl chloride and followed
by LiBr. Bergaptol (9) was then alkylated with compound 8 in dry acetone in the presence of K2CO3
and catalytic amount of sodium iodide to afford SL-BM (10) (Scheme 2).
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Scheme 1. Reagents and conditions: (i) potassium carbonate, ethyl acetoacetate, 18-crown-6, anhydrous
acetone, 24 h reflux, 67%; (ii) 10% aqueous NaOH, ethanol, 30 min reflux followed by 24 h stirring at
room temperature, then 5% H2SO4, 59%; (iii) NaH, anhydrous toluene, triethyl phosphonoacetate,
N2 atmosphere, 30 min reflux, 45%; (iv) SMEAH, abs. toluene, N2 atmosphere, −30 ◦C, then room
temperature for 30 min, 83%.
Scheme 2. Reagents and conditions: (i) dry CH2Cl2, triethylamine, methanesulfonyl chloride at −30 ◦C,
then LiBr, anhydrous acetone, 40 ◦C, 30 min, 72%; (ii) anhydrous acetone, K2CO3, NaI (cat.), 40 ◦C,
24 h, N2 atmosphere, 20%.
2.3. Inhibition of the CYP Enzymes by BM and SL-BM
BM proved to be a strong inhibitor of each CYP enzyme tested, while SL-BM showed considerable
inhibitory effects toward the CYP2C19 and CYP3A4 enzymes (Figure 2). BM was a two-fold stronger
inhibitor of CYP2C9 than the positive control warfarin (Table 1); the inhibitory effect induced by SL-BM
was also statistically significant, but only a slight decrease in metabolite formation resulted (even at a
four-fold concentration vs. the substrate). SL-BM was approximately two times weaker, while BM
induced almost a seven-times stronger inhibitory effect toward CYP2C19 relative to the inhibitory
effect of the positive control ticlopidine. Despite the fact that BM proved to be a considerably stronger
inhibitor of both the CYP2C enzymes tested, SL-BM showed a significantly stronger inhibitory action
toward CYP3A4 (Figure 2). BM and SL-BM were 1.7 and 8.5 times weaker inhibitors of CYP3A4 than
the positive control ketoconazole (Table 1).
Figure 2. Concentration-dependent inhibitory effects of BM, SL-BM, and positive controls (WAR,
warfarin; TIC, ticlopidine; KET, ketoconazole) towards the CYP2C9, CYP2C19, and CYP3A4 enzymes
(* p < 0.05, ** p < 0.01). Data points indicate the means obtained from triplicate incubations ± SEM.
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Table 1. Inhibition of the CYP2C9, CYP2C19, and CYP3A4 enzymes by BM, SL-BM, and positive controls.
CYP2C9 Assay Substrate Concentration (µM) IC50 (µM) 1 IC50(rel) 2 α 3
Warfarin (positive ctrl) 15 29.4 1.96 1.00
Bergamottin 15 14.7 2.94 0.50
SL-Bergamottin 15 >60.0 >4.00 -
CYP2C19 Assay Substrate Concentration (µM) IC50 (µM) 1 IC50(rel) 2 α 3
Ticlopidine (positive ctrl) 5 7.67 1.53 1.00
Bergamottin 5 1.01 0.20 0.13
SL-Bergamottin 5 14.6 2.92 1.90
CYP3A4 Assay Substrate Concentration (µM) IC50 (µM) 1 IC50(rel) 2 α 3
Ketoconazole (positive ctrl) 5 0.24 0.05 1.00
Bergamottin 5 2.04 0.41 8.50
SL-Bergamottin 5 0.40 0.08 1.67
1 IC50: concentration of the inhibitor which induces 50% inhibition of the metabolite formation; 2 IC50(rel): IC50
of the inhibitor divided by the substrate concentration; 3 α: IC50 of the inhibitor divided by the IC50 value of the
positive control.
2.4. Modeling Studies
Ligands KET, BM, and 10 were docked to the binding pocket of CYP3A4, which is located above
the heme ring. The docking of KET tested the applicability of the methodology for producing a close
to crystallographic bound KET conformation. In the cases of BM and SL-BM, the binding modes were
de novo, as described in the present study.
Binding mode of KET. According to the holo CYP3A4 crystallographic structure (Protein Data
Bank (PDB) code 2v0m), KET (Table 2) is coordinated to the iron of the heme with a nitrogen of the
imidazole ring, and the distance between the N atom and Fe3+ is 2.7 Å. Interacting amino acid residues
are listed in Table 2. The heme-bound crystallographic ligand conformation of KET was used to
verify the applicability of our computational docking protocol (see Methods for details) for the atomic
resolution calculation of the KET binding mode. The docking of KET into the ligand-free binding
pocket of the 2v0m structure was successful, and the crystallographic ligand binding mode of KET
was reproduced at an RMSD value of 2.3 Å (Figure 3) in the top 2nd rank. The main interactions
were reproduced. That is, the phenyl rings of F304 and KET were parallel, forming pi–pi interactions,
and A370 formed a hydrophobic interaction with the methyl group of KET. The positively charged
sidechain of R372 interacted with the partial negative charge of the oxo group of KET.
Binding modes of BM and SL-BM. To determine the binding modes of BM and SL-BM,
the same docking protocol was applied as that used in the case of KET, as described in the previous
paragraph. In both cases, the top 1st rank binding mode was very similar to that of KET (Figure 4).
The furo[3,2-g]chromen-7-one ring was located above the heme occupying the subpockets of the
imidazole ring of KET. The furan oxygen was coordinated to the heme for both ligands. The O–Fe3+
distances were 4.0 and 4.2 Å for compounds 10 and 1, respectively (Figure 5). In the bound position,
the furo[3,2-g]chromen-7-one ring of the ligands occupied the same subpocket and their side-chains
were also in a similar position. The furo[3,2-g]chromen-7-one ring of the ligands was parallel to the
heme, possibly forming pi-stacking interactions, which was similar to KET (as described in the previous
paragraph). Eight and seven amino acid residues were found to interact (Methods) with SL-BM
and BM, respectively; of which five residues were common. Compounds 10 and 1 both interacted
with CYP3A4 through H-bonds between the hydrophilic amino acid (T309) and the furan oxygen.
Hydrophobic interactions occurred between the M114, F241, I301, and F304 amino acids and the methyl
groups of the ligands. F304 played a role in the binding of each (KET, BM, and SL-BM) ligand (Table 2).
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Table 2. Binding properties of the ligands to the CYP3A4 target. X represents the amino
acid-ligand interactions.
Ligand KET SL-BM BM
Rank of the docking of the ligand 2 1 1
O–Fe dist (Å) 4.2 4
N–Fe dist (Å) 3.8
Calculated binding free energies ∆Gbind(kcal/mol) [33] −9.4 −10.4 −9.2
List of interacting amino acidresidues
M114 X X
S119 X
L210 X
L211 X
F241 X X
I301 X X
F304 X X X
A305 X
T309 X X
A370 X X
R372 X
G481 X
Figure 3. The docked (red) binding mode of KET overlaps with its crystallographic binding mode
(blue), which is located above the heme ring (not shown).
Figure 4. The binding mode of SL-BM (space-filling) as docked to the binding pocket of the CYP3A4
enzyme (light blue cartoon) above the heme ring (green sticks), where iron is represented as an orange
sphere. Red spheres represent the oxygen, the blue sphere the nitrogen of SL-BM respectively.
Int. J. Mol. Sci. 2020, 21, 508 6 of 13
Figure 5. The close-up of the binding mode of SL-BM (left) and BM (right) (wide sticks) as docked to
the binding pocket of the CYP3A4 enzyme above the heme ring (wide sticks) where iron is represented
as an orange sphere. Interacting enzyme residues are labelled and shown as thin sticks.
2.5. Cytotoxicity of BM and SL-BM
The cytotoxicity of BM and SL-BM was analyzed by a WST Cell Viability & Proliferation assay
performed using NIH3T3 (murine embryonic fibroblast) and HeLa (human cervix carcinoma) cells.
Neither bergamottin nor SL-bergamottin showed a significant toxicity toward fibroblasts (IC50 > 50 µM).
BM did not decrease the viability of the HeLa cells (IC50 > 50 µM); however, SL-BM induced a significant
loss in the viability of the HeLa cell line (IC50 = 17.32 µM). These results demonstrate the selective toxicity
of SL-BM toward cancer cells (Figure 6).
Figure 6. Concentration-dependent cytotoxic effects of BM and SL-BM on NIH3T3 fibroblasts and HeLa
carcinoma cells. The cells were treated with BM or SL-BM for 24 h (* p < 0.05, ** p < 0.01). The data
points represent the means ± SD (n = 6).
Int. J. Mol. Sci. 2020, 21, 508 7 of 13
3. Discussion
A new nitroxide moiety containing bergamottin analog (10) has been synthesized and evaluated
for use as an inhibitor of CYP (2C9, 2C19, and 3A4) enzymes and compared to bergamottin (1) and
known inhibitors of these enzymes. The cytotoxicity toward cancer and noncancer cell lines was
also investigated.
BM induced a 50% inhibition of the metabolite formation at 0.2- and 0.4-fold concentrations vs.
the substrates in the CYP2C19 and CYP3A4 assays, respectively (Table 1). The IC50 values of BM
toward these enzymes were in the low micromolar range, which agrees well with the previously
reported data [14,34–36]. Furthermore, BM proved to also be an inhibitor of CYP2C9, showing 50%
inhibition of metabolite formation at approximately a three-fold concentration vs. the substrate.
Previous studies also reported the significant inhibitory effect of BM on CYP2C9 enzymes [11,14,35–37].
As our results demonstrated, SL-BM only slightly inhibits CYP2C9 and is almost a 15-fold weaker
inhibitor of CYP2C19 than BM (Table 1). However, SL-BM was a five-fold stronger inhibitor of CYP3A4
compared to BM, showing a strong inhibitory efficacy similar to that of the positive control ketoconazole.
The enhanced inhibitory activity of SL-BM compared to that of BM was also supported by docking
experiments, where the binding of SL-BM was more favorable than that of BM (∆Gbind(−10.4 vs.
−9.2 kcal/mol)). The difference in the inhibitory activities of SL-BM and BM may be attributed to the
H-acceptor property of the nitroxide, as it was suggested by Row et al. [11].
BM and SL-BM seemed to be nontoxic to normal cells since they did not significantly decrease the
viability of NIH3T3 fibroblasts in our toxicity assay. As far as we know, this is the first report about
the anticancer activity of bergamottin toward HeLa cells. As shown in previous reports, although
BM showed an inhibition effect on many cancer cell lines, such as HT-1080 fibrosarcoma [17], U266
multiple myeloma [18], HepG2 liver cancer, BGC-823 gastric cancer, HL-60 promyelotic leukemia [38],
and A549 lung cancer cells [16], we did not observe BM to be significantly cytotoxic toward the
HeLa cell line. Nevertheless, the insertion of a nitroxide moiety (10, IC50. = 17.32 µM) resulted in the
cancer-specific cytotoxic activity of the parent compound (1, IC50 > 50 µM). Therefore, compound 10
may be a good starting point for the development of new CYP3A4 enzyme inhibitors with elevated
anti-proliferative effects.
4. Materials and Methods
4.1. Chemistry
4.1.1. General
The mass spectra were recorded with a Thermoquest Automass Multi system (ThermoQuest,
CE, Instruments, Milan, Italy) operated in EI mode (70 eV). Elemental analyses were carried out
with a Fisons EA 1110 CHNS elemental analyzer (Fisons Instruments, Milan, Italy) The melting
points were determined with a Boetius micro-melting point apparatus (Franz Küstner Nachf. K.
G., Dresden, Germany). The 1H NMR spectra were recorded with a Bruker Avance 3 Ascend 500
system (Bruker BioSpin Corp., Karsluhe, Germany) operated at 500 MHz, and the 13C NMR spectra
were obtained at 125 MHz in CDCl3 or DMSO-d6 at 298 K. The “in situ” reduction of the nitroxides
was achieved by the addition of five equivalents of hydrazobenzene (DPPH/radical). The IR spectra
were obtained with a Bruker Alpha FT-IR instrument (Bruker Optics, Ettlingen, Germany) with an
ATR support on a ZnSe plate. Flash column chromatography was performed on Merck Kieselgel
60 (0.040–0.063 mm). Qualitative TLC was carried out on commercially available plates (20 cm ×
20 cm × 0.02 cm) coated with Merck Kieselgel (Darmstadt, Germany) GF254. Compound 3 [32],
was synthesized as previously described. All the other reagents were purchased from Sigma Aldrich
(St. Louis, MO, USA), Molar Chemicals (Halásztelek, Hungary) or TCI (Tokyo, Japan). 1H-NMR and
13C-NMR spectra of new compounds are available as supporting data (see Supplementary Materials).
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4.1.2. Preparation of Compounds
Ethyl 2-acetyl-4-(1-oxyl-2,2,6,6-tetramethyl-piperidin-4-ylidene)butanoate (4): Potassium carbonate
(11.09 g, 80.0 mmol), ethyl acetoacetate (6.50 g, 50.0 mmol), and 18-crown-6 (10 mg) were dissolved in
anhydrous acetone (30 mL), allylic bromide (3) (2.61 g, 10.0 mmol) dissolved in dry acetone (10 mL)
was added dropwise, and the mixture was stirred and refluxed for 24 h. The solvent was evaporated,
the residue was partitioned between H2O (25 mL) and CH2Cl2 (30 mL), after separation of the phases,
the water phase was extracted with further CH2Cl2 (2 × 20 mL). The combined organic phases were
dried over MgSO4, filtered, evaporated, and the residue was purified by column chromatography
(hexane-Et2O) to achieve compound 4 2.07 g (67%) as a red oil. Rf: 0.2 (hexane-Et2O, 2:1), MS m/z (%):
310 (M+,42), 166 (13), 135 (100), 107 (56). Anal. calcd. for C17H28NO4. C 65.78; H 9.09; N 4.51, Found:
C 65.55, H 9.36, N 4.42. IR (neat): ν = 1738, 1714 cm −1. 1H NMR (500 MHz, CDCl3 + (PhNH)2): δ =
5.21 (t, 1H, J = 7.3 Hz), 4.26 (q, 2H, J = 7.1 Hz), 3.53 (t, 1H, J = 7.5 Hz), 2.67 (dt, 2H, J = 7.3, 2.1 Hz), 2.29
(s, 3H), 2.23 (s, 2H), 2.12 (s, 2H), 1.33 (t, 3H, J = 7.1 Hz), 1.20, 1.17 (2s, 12H). 13C NMR (125 MHz, CDCl3
+ (PhNH)2): δ = 202.7, 169.5, 135.5, 121.1, 61.5, 60.2, 59.9, 49.5, 41.6, 29.2, 26.4, 14.2.
5-(1-Oxyl-2,2,6,6-tetramethylpiperidin-4-ylidene)pentan-2-one (5): To the ethanolic (20 mL) solution of
ketoester (4) (1.55 g, 5.0 mmol), 10% aqueous NaOH (20 mL) was added, and the mixture was refluxed
for 30 min. After additional 24 h stirring at room temperature, the solvent was evaporated off and the
residue was acidified with 5% H2SO4 and extracted with EtOAc (3 × 20 mL). The combined organic
phases were dried (MgSO4), filtered, evaporated, and purified by flash column chromatography
(hexane-Et2O) to yield compound 5 as a red oil, 702 mg (59%); Rf: 0.23 (hexane-Et2O, 2:1). MS (EI):
m/z (%) = 238 (M+, 41), 224 (100), 180 (16), 166 (60), 43 (100). Anal. calcd. for C14H24NO2: C, 70.55; H,
10.15; N, 5.88. Found: C, 70.39; H, 10.21; N, 5.77. IR (neat): ν = 1714, 1633 cm−1. 1H NMR (500 MHz,
CDCl3 + (PhNH)2): δ = 5.23 (t, 1H, J = 7.2 Hz), 2.50 (t, 2H, J = 7.5 Hz), 2.35 (q, 2H, J = 7.4 Hz), 2.20 (s,
2H), 2.16 (s, 3H), 2.11 (s, 2H), 1.19, 1.17 (2s, 12H). 13C NMR (125 MHz, CDCl3 + (PhNH)2): δ = 208.4,
133.4, 124.0, 60.3, 60.2, 49.4, 43.9, 41.6, 30.0, 22.0.
(E)-Ethyl 6-(1-oxyl-2,2,6,6-tetramethylpiperidin-4-ylidene)-3-methylhex-2-enoate (6): To a stirred
suspension of NaH (96 mg, 4.0 mmol) in dry toluene (15 mL), triethyl phosphonoacetate (1.12 g,
5.0 mmol) was added at 0 ◦C under a N2 atmosphere. After stirring for 10 min, 5 ketone (720 mg,
3.0 mmol) was added, and the mixture was stirred and refluxed for another 30 min. After cooling to
room temperature, brine (20 cm3) and ether (20 cm3) were added, the organic phase was separated,
and the aqueous phase was washed with ether (2 × 20 cm3). Then, the combined organic phase was
dried (MgSO4), filtered and evaporated, and the residue was purified by flash column chromatography
(hexane-Et2O) to yield 315 mg (34%) of compound 6 as a reddish-brown oil. Rf: 0.40 (hexane-Et2O,
2:1); MS m/z (%) 308 (M+, 38), 278 (6), 166 (11), 74 (100). Anal. calcd. for C18H30NO3: C, 70.09; H, 9.80;
N, 4.54. Found: C, 70.19; H, 9.91; N, 4.60. IR (neat): ν = 1713, 1648 cm −1. 1H NMR (500 MHz, CDCl3 +
(PhNH)2): δ = 5.78 (s,1H), 5.25 (t, 1H, J = 6.3 Hz), 4.24 (q, 2H, J = 7.1 Hz), 2.30–2.24 (m, 5H), 2.21 (s, 2H),
2.14 (s, 2H), 1.36 (t, 3H, J = 7.1 Hz), 1.21 (s, 6H), 1.19 (s, 6H). 13C NMR (125 MHz, CDCl3 + (PhNH)2): δ
= 166.8, 159.3, 133.2, 124.4, 116.0, 60.3, 60.2, 59.5, 49.5, 41.7, 41.2, 25.7, 18.9, 14.4.
(E)-4-(6-hydroxy-4-methylhex-4-en-1-ylidene)-2,2,6,6-tetramethylpiperidin-1-yloxy (7): To a stirred
solution of ester (6) (716 mg, 2.0 mmol) in abs. toluene (20 mL), SMEAH (1.21 g, 6.0 mmol) dissolved in
toluene (10 mL) was added dropwise under N2 at −30 ◦C. Then, the mixture temperature was allowed
to rise to room temperature, and the reaction was stirred for a further 30 min. After completion of the
reaction, the solution was added in portions to the mixture of 10 % NaOH (25 mL) and crushed ice
(50 g). The phases were separated, and the aqueous phase was extracted with a mixture of THF/Et2O
(1:4) (3 × 20 mL). The combined organic phases were dried (MgSO4), filtered, and evaporated. The title
compound (7) was obtained after column chromatography (hexane-EtOAc) as a red oil (440 mg, 83%).
Rf: 0.23 (hexane/EtOAc, 2:1), MS m/z (%) 266 (M+, 43), 95 (51), 74 (100), Anal. calcd. for C16H28NO2:
C, 72.14; H, 10.59; N, 5.26. Found: C, 72.31; H, 10.51; N, 5.37. IR (neat): ν = 3412, 1670, 1098 cm −1.
1H NMR (500 MHz, CDCl3 + (PhNH)2): δ = 5.48 (dt,1H, J = 6.9, 1.2 Hz), 5.26 (t, 1H, J = 7.0 Hz). 4.21 (d,
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2H, J = 6.8 Hz), 2.23–2.19 (m, 4H), 2.14–2.10 (m, 4H), 1.73 (s, 3H), 1.19 (s, 6H), 1.17 (s, 6H). 13C NMR
(125 MHz, CDCl3 + (PhNH)2): δ = 139.2, 132.3, 125.3, 123.7, 60.3, 60.2, 59.4, 49.5,41.6, 39.8, 25.9 16.3.
(E)-4-(6-bromo-4-methylhex-4-en-1-ylidene)-2,2,6,6-tetramethylpiperidin-1-yloxy (8): To the stirred
solution of compound 7 (532 mg, 2.0 mmol) and triethylamine (222 mg, 2.2 mmol) in dry CH2Cl2
(20 mL), after cooling to −30 ◦C, methanesulfonyl chloride (249.3 g, 2.2 mmol) was added dropwise.
After the mixture temperature increased to room temperature, brine (20 mL) was added, the phases
were separated, and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined organic
phases were dried over MgSO4, filtered, and evaporated. The residue was dissolved in anhydrous
acetone (30 mL), to which LiBr (522 mg, 6.0 mmol) was then added, and the mixture was stirred
at 40 ◦C for 30 min. Water (20 mL) and Et2O (15 mL) were added, and after separation, the water
phase was extracted with further Et2O (2 × 20 mL). The combined organic phases were dried over
MgSO4, filtered, and evaporated to achieve paramagnetic geranyl bromide (8) as a reddish-brown oil
with a 72% (410 mg) yield. MS m/z (%) 284/286 (M+, 5/2), 248 (6), 109 (13,) 107 (21), 95 (40), 74 (100).
NMR measurements cannot be performed without the loss of the bromide function in the presence
of hydrazobenzene.
(E)-4-((6-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)-3-methylhex-2-en-1-yl)oxy)-7H-furo[3,2
-g]chromen-7-one (10): Bergaptol (9) (202 mg, 1.0 mmol) was dissolved in anhydrous acetone (10 mL),
K2CO3 (276 mg, 2.0 mmol), NaI (19.5 mg, 0.13 mmol), and bromide 8 (427 mg, 1.5 mmol) were
added and the mixture was stirred at 40 ◦C for 24 h under a N2 atmosphere. After cooling to room
temperature, brine (20 mL) and CH2Cl2 (20 mL) were added, the organic phase was separated,
and the aqueous phase was washed with CH2Cl2 (2 × 20 mL). Then, the combined organic phase was
dried (MgSO4), filtered, evaporated, and the residue was purified by flash column chromatography
(hexane-EtOAc) to yield the title compound 10 as red crystals, 90 mg (20 %). M.p.: 51–53 ◦C. Rf: 0.43
(hexane-EtOAc, 2:1). MS m/z (%) 450 (M+, 3), 435 (3), 420 (5), 202 (25), 98 (66), 74 (100) Anal. calcd.
for C27H32NO5: C 71.98; H 7.16; N 3.11. Found: C, 72.11; H, 7.20; N, 3.17. IR (neat): ν = 1725, 1623,
1332 cm −1. 1H NMR (500 MHz, CDCl3 + (PhNH)2): δ = 8.19 (d, 1H, J = 9.8 Hz), 7.60 (d, 1H, J = 2.3 Hz),
7.20 (s, 1H), 6.96 (d, 1H, J = 2.3), 6.32 (d, 1H, J = 9.8 Hz), 5.95 (dt,1H, J = 6.8, 1.0 Hz), 5.23 (t, 1H, J =
6.8 Hz), 4.97 (d, 2H, J = 6.8 Hz), 2.24–2.18 (m, 6H), 2.10 (s, 2H), 1.75 (s, 3H), 1.18 (s, 6H), 1.16 (s, 6H).
13C NMR (125 MHz, CDCl3 + (PhNH)2): δ = 161.2, 158.1, 148.9, 144.9, 142.6, 139.5, 132.7, 124.8, 119.2,
114.2, 112.6, 107.5, 105.0, 94.2, 69.7 60.3, 60.2, 49.5, 41.7, 39.8, 25.7, 16.7.
4.2. CYP Inhibition Assays
4.2.1. Reagents
Testosterone, 6β-hydroxytestosterone, ketoconazole, racemic warfarin, ticlopidine hydrochloride,
CypExpressTM 2C9 kit, CypExpressTM 2C19 kit, and CypExpressTM 3A4 kit were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Diclofenac, 4′-hydroxydiclofenac, S-mephenytoin,
and 4-hydroxymephenytoin were obtained from Carbosynth (Compton, Berkshire, UK).
4.2.2. CYP Assays
Stock solutions of BM, SL-BM, and positive controls (each 5000 µM) were prepared in dimethyl
sulfoxide (Fluka) and stored at –20 ◦C. The inhibitory effects of BM and SL-BM on the CYP2C9,
2C19, and 3A4 enzymes were examined using CypExpressTM assay kits by employing diclofenac,
S-mephenytoin, and testosterone substrates, respectively. During these assays, racemic warfarin (2C9),
ticlopidine (2C19), and ketoconazole (3A4) were applied as positive controls. The CYP2C9, 2C19,
and 3A4 assays were performed as described in our previous studies [39–42].
The substrates and products were analyzed using the HPLC system comprising a pump (Waters
510; Milford, MA, USA), an injector (Rheodyne 7125) with a 20 µL sample loop, and a UV detector
(Waters 486). The data were evaluated by employing Millennium Chromatographic Manager
software (Waters). HPLC analyses of diclofenac and 4′-hydroxydiclofenac (CYP2C9 assay) [39,40],
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S-mephenytoin, and 4-hydroxymephenytoin [42] as well as testosterone and 6β-hydroxytestosterone
(CYP3A4 assay) [41] were performed as described previously.
Data were derived from at least three independent experiments and represented as the mean
± the standard error of the mean (SEM) values. The statistical significance (p < 0.05 and p < 0.01)
was established by employing a one-way ANOVA test (IBS SPSS Statistics, v. 21; Armonk, NY, USA).
The metabolite formation (% of control) was plotted as a function of the logarithmic concentrations,
and then the IC50 values were determined using GraphPad Prism 8 software (San Diego, CA, USA).
4.3. Modeling Studies
4.3.1. Ligand Preparation
The raw ligand structures of ketoconazole, bergamottin (BM, 1), and SL-BM (10) were built
in Maestro [43] and energy-minimized with a quantum chemistry program package, MOPAC [33],
with PM7 parametrization [44]. Force calculations were also performed using MOPAC, in which
the gradient norm was set to 0.001, and the force constant matrices were positive and definite.
Gasteiger–Marsilli partial charges were assigned in AutoDock Tools [45]. Flexibility was allowed on
the ligand at all active torsions. These prepared structures were used for docking.
4.3.2. Target Preparation
Similar to a previous study [46], the holo structure of CYP3A4 in the complex with ketoconazole
was used as a target. The atomic coordinates of the complex were obtained from the Protein Data Bank
(PDB) with PDB code 2v0m. The bound ketoconazole molecules were removed prior to the docking
calculations, and chain A was processed further as a target. The atomic partial charges of the heme
were adopted as the ferric penta coordinate high-spin charge model from reference [47]. The rest of the
target molecule was equipped with polar hydrogen atoms and Gasteiger–Marsilli partial charges in
AutoDock Tools.
4.3.3. Docking
All the ligand structures were docked to the active site of CYP3A4 using AutoDock 4.2.6 [45].
The number of grid points was set to 90 × 90 × 90 using a 0.375 Å grid spacing. The Lamarckian
genetic algorithm was used for the global search, and the flexibility of all active torsions was allowed
on the ligand. Ten docking runs were performed, and the resulting ligand conformations were ranked
by their free binding energy values. Representative docked ligand conformations were used for the
subsequent evaluations, and a collection of interacting target amino acid residues with a 3.5 Å cut-off
distance were calculated for heavy atoms. The root-mean-squared deviation (RMSD) values were
calculated between the crystallographic and representative ligand conformations.
4.4. Cell Viability Assays
Murine embryonic fibroblast NIH3T3 cells were maintained in DMEM (Cat No. 043-30085, Wako
Pure Chemical, Osaka, Japan) supplemented with 10% newborn calf serum (NBCS) at 37 ◦C and
5% CO2. Human cervix carcinoma HeLa cells were maintained in DMEM supplemented with 10%
fetal bovine serum at 37 ◦C and 5% CO2. To determine the toxicity of BM and SL-BM, the WST-1
cell viability assay was employed as described previously [26]. The cells (NIH3T3: 2000 per well;
HeLa: 5000 per well) were seeded into all the wells of 96-well plates. After 24 h, the medium was
replaced, and the cells were treated with the test compounds for 24 h. Then, the cells were incubated
with a WST-1 solution (3.6 µg/µL WST-1, 70 ng/µL 1-methoxy phenazine methosulfate in 20 mM
4-(2-hydroxyethyl)-1-piperazineethanesufonic acid–KOH (pH 7.4); Dojindo, Kumamoto, Japan) for 1 h
at 37 ◦C, and the absorbance of each well was recorded at 440 nm using a Multiskan FC microplate
reader (Thermo Fisher Scientific). The IC50 values and statistical significance were calculated using
GraphPad Prism 8 software (San Diego, CA, USA).
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